UroGen Pharma Ltd. Inventory, Finished Goods, Net of Reserves
UroGen Pharma Ltd. (URGN) had Inventory, Finished Goods, Net of Reserves of $16.86 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-05
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $16.86M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $11.16M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $5.42M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $3.58M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $16.86M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $11.16M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $5.42M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $3.58M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $3.81M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.53M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $4.52M 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.93M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.96M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $3.59M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $2.88M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.74M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.07M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.96M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.02M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.86M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.03M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.37M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.96M 10-K · filed 2023-03-24 |
| 2021-09-30 | $1.27M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $913.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |